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Abstract
Background: In 2009 the Uterine Bleeding and Pain Women’s Research Study (UBP-WRS) was conducted
interviewing 21,479 women across 8 countries in order to gain patient-based prevalence data on uterine pain and
bleeding indications and investigate uterine symptoms and women’s treatment experiences. This article shows
relevant results of the study for the indication uterine fibroids providing data on self-reported prevalence,
symptomatology and management of uterine fibroids.
Methods: 2,500 women (USA: 4,500 women) in each country (Brazil, Canada, France, Germany, Italy, South Korea,
the UK, the USA) completed an online survey. Women included were in their reproductive age (age group 15-49
years; USA: 18-49 years) and had ever experienced menstrual bleedings. Quotas were applied for age, region, level
of education and household income of respondents. Variables have been analyzed descriptively and exploratory
statistical tests have been performed.
Results: The self-reported prevalence of uterine fibroids ranged from 4.5% (UK) to 9.8% (Italy), reaching 9.4% (UK)
to 17.8% (Italy) in the age group of 40-49 years. Women with a diagnosis of uterine fibroids reported significantly
more often about bleeding symptoms than women without a diagnosis: heavy bleedings (59.8% vs. 37.4%),
prolonged bleedings (37.3% vs. 15.6%), bleeding between periods (33.3% vs. 13.5%), frequent periods (28.4% vs.
15.2%), irregular and predictable periods (36.3% vs. 23.9%). Furthermore women with diagnosed uterine fibroids
reported significantly more often about the following pain symptoms: pressure on the bladder (32.6% vs. 15.0%),
chronic pelvic pain (14.5% vs. 2.9%), painful sexual intercourse (23.5% vs. 9.1%) and pain occurring mid-cycle, after
and during menstrual bleeding (31.3%, 16.7%, 59.7%, vs. 17.1%, 6.4%, 52.0%). 53.7% of women reported that their
symptoms had a negative impact on their life in the last 12 month, influencing their sexual life (42.9%),
performance at work (27.7%) and relationship & family (27.2%).
Conclusions: Uterine fibroid is a common concern in women at fertile age causing multiple bleeding and pain
symptoms which can have a negative impact on different aspects in women’s life.
Background
Uterine fibroids (myomas or leiyomymas) are benign,
monoclonal tumors of the smooth muscle cells found in
the human uterus [1,2]. Despite the fact that their cause
is still unknown, yet there is considerable evidence that
estrogens and progestogens proliferate tumor growth
[3,4], as the fibroids rarely appear before menarche [5]
and regress after menopause [6]. Uterine fibroids are the
most common benign tumors in women and the leading
indication for hysterectomies in the USA [7,8], neverthe-
less, epidemiological data on fibroid prevalence and inci-
dence are limited and reliable population-based research
is lacking [9]. Available data are difficult to compare
due to differences in the study population and screening
methods. Prevalence data range from 5% to 21%
[10-13]. In a US study with randomly selected women
between 35 to 49 years, who were screened by self-
report, medical record and sonography, the incidence of
uterine fibroids by age 35 was 60% among African-
American women, increasing to > 80% by age 50,
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by age 35, and almost 70% by age 50 [14]. Apart from
race, other possible risk factors for developing uterine
fibroids are early age at menarche [15], familial predis-
position [16] and overweight [17,18]. Parity [15,19-21]
and smoking may protect from developing myomas
[17,19,20,22].
The majority of women with uterine fibroids are
asymptomatic, consequently get less clinical attention
and fibroid tumors often remain undiagnosed [23,24].
Symptomatic women typically complain about abnormal
uterine bleeding, specifically in terms of heavy and pro-
longed bleeding [25]. In a study of Wegienka et al.
(2004) women with myomas were more likely to report
a “gushing"-type of bleeding and high pad/tampon use
than women without myomas [26]. Additionally, women
with uterine fibroids may suffer more often from dys-
pareunia and non-cyclic pelvic pain [27]. Although
bleeding and pelvic pain symptoms are frequently
reported in literature as main symptoms related to uter-
ine fibroids, the number of systematic studies on fibroid
symptoms is limited.
Therapeutic options to treat these symptoms include
medical therapy, surgical interventions and uterine
artery embolization [28]. Medical treatments used to
manage bleeding symptoms are oral contraceptives or
progestins, although there is no evidence for their effi-
cacy in treating myomas [29]. Other medical alternatives
are the Levonorgestrel-releasing intrauterine system
(LNG-IUS) and GnRH-agonists. However, the LNG-IUS
cannot be applied in case of significant distortion of the
uterine cavity and the duration of treatment with
GnRH-agonists is limited by the induction of hypoestro-
genic symptoms. According to the reproductive desire
of the patient and the severity of symptoms surgical
procedures comprise myomectomy, endometrial ablation
or hysterectomy.
In 2009 the Bayer Healthcare Pharmaceuticals initiated
the Uterine Bleeding and Pain Women’s Research Study
(UBP-WRS), an internet-based-study across 8 countries.
The objective of this large study was to gain patient-
based prevalence data on uterine pain and bleeding indi-
cations and investigate uterine symptoms and women’s
treatment experiences. This article shows relevant
results of the study for the indication uterine fibroids.
According to our knowledge it is the largest interna-
tional population-based study available on self-reported
prevalence, symptomatology and management of uterine
fibroids. It allows for cross country-comparison regard-
ing prevalence data and management of uterine fibroids
and reveals differences in symptomatology and risk fac-
tors in comparison with women without a diagnosis of
uterine fibroids.
Methods
Recruitment and study population
The UBP-WRS is a cross-sectional study using an
online-method approach. The online survey was con-
ducted during November and December 2009 across 8
countries including Brazil, Canada, France, Germany,
Italy, South Korea, the UK and the USA. In order to
reach appropriate potential participants of women in a
representative manner across countries, study partici-
pants were recruited via an online-panel. The panel is
hosted by the online market research service provider
Global Market Insite (GMI), a certified member of the
European Society for Opinion and Marketing Research
(ESOMAR). Panelists are recruited from more than 500
sources, such as web advertising or permission-based
databases and sign up to participate by filling out a
comprehensive online registration form. In a second
step panelists activate their account by clicking a link
sent to them via email immediately after registration.
Panel information is updated on a regular basis through-
out the year and panel members receive a maximum of
4 different surveys per month across a variety of topics
and in their native languages.
Inclusion criteria were: women in their reproductive
age (age group 15-49 years, except USA: 18-49 years
due to legal restrictions) who have ever experienced
menstrual bleedings. In order to collect a cohort of
women representative of the general population, quota
limits within each country based on available national
statistics or census data were enforced for age, geo-
graphic region, level of education and household
income. Within-country population limits for data
acquisition were relaxed after 80% of the sample size
had been achieved.
Institutional Review Board (IRB)/Ethics Committee
decided approval was not required for this study.
Data collection
2,500 women per country (USA: 4,000 women) meeting
the inclusion criteria and the quotas were enrolled in
the study. The survey instrument was a self-adminis-
tered online-survey written in English and translated in
Spanish, Portuguese, German, Italian, French and Kor-
ean, accounting for local language characteristics. The
survey took approximately 45 minutes to complete and
collected data in a number of categories: demographics,
patient characteristics, aspects of the menstrual cycle,
health care visits, diagnosed conditions, symptoms,
treatments received, surgeries and impact on life. Those
women, who answered that their doctor or another
health professional has ever told them the diagnosis of
uterine fibroids, form the uterine fibroid population in
this study. The comparison group is defined as those
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fibroids from their doctor or health professional. The
survey also included questions designed to identify gyne-
cological conditions other than uterine fibroids, such as
endometriosis. These findings will be reported elsewhere
[30].
Statistical methods
All variables were analyzed using descriptive statistical
methods, giving the number of non-missing observa-
tions, mean, and standard deviation for metric variables
and absolute and relative frequency counts for categori-
cal variables. Observations were age-weighted within
each country according to census data. Missing response
items were not imputed.
Exploratory statistical tests were performed to test the
null hypothesis that there was no difference between
women with and without a diagnosis of uterine fibroids.
The c
2-test was used for categorical data and analysis of
variance for metric data. In addition, logistic regression
was applied to analyze the influence of age and co-mor-
bidities like endometriosis and adenomyosis in addition
to the occurrence of uterine fibroids. All statistical tests
u s e das i g n i f i c a n c el e v e la of 5%. As appropriate for
exploratory analyses, no corrections for multiple testing
were performed. 95-% Confidence Intervalls (CI) for the
proportions were calculated using the exact Clopper-
Pearson method. The statistical analyses were performed
using SPSS software.
Results
Study participation
In total, 251,181 women were invited to participate in
the survey, of which 14.6% (n = 36,770) entered screen-
ing; a further 11,607 (4.6%) were filtered out during the
screening stage. Of the remaining population (n =
25,163), 1.4% (n = 3,414) of all women invited either did
not complete the survey and were excluded, or were
eliminated by quality control procedures. Between 2,500
and 2,558 surveys were completed by participants in
each of the eight countries, with the exception of the
USA, in which 4,039 surveys were submitted (see Table
1). The final survey populati o nu s e di nd a t aa n a l y s i s
comprised 21,746 women aged 15-49 years (USA: age
range 18-49 years).
Self-reported prevalence
The self-reported prevalence of uterine fibroids ranged
from a low of 4.5% in UK and 4.6% in France to a high
o f9 . 8 %i nI t a l ya n d9 . 0 %i nK o r e a( s e eF i g u r e1 ) .
Although prevalence increased with age, already 1.8% of
the 20 to 29 year old women received a diagnosis (see
Table 2). Self-reported prevalence in the age group of
40 years and older rose to 14.1% across all countries,
ranging from 9.4% in UK (n = 45) to 17.8% in Italy (n =
86).
Risk Factors
With a mean age of 40.4 ± 6.9 years women who
reported a diagnosis of uterine fibroids (n = 1,533) were
in average 8 years older than women without the diag-
nosis (mean age 32.4 ± 9.6 years; n = 20,213; p < 0.001).
There was no statistical difference in the mean age at
menarche between both groups (diagnosed women with
uterine fibroids: 12.9 ± 1.9 years; undiagnosed women:
12.9 ± 2.1 years; p = 0.220). The percentage of women
having children was higher among women with diag-
nosed uterine fibroids (67.1%) compared to women
without a diagnosis (46.2%). After adjusting for age, this
difference disappears.
Bleeding Symptoms
The frequency of uterine bleeding symptoms of women
who reported a diagnosis of uterine fibroids in compari-
son to women without a diagnosis of uterine fibroids is
shown in Table 3. About 59.8% of women with a uterine
fibroid diagnosis experienced heavy bleedings compared
to 37.4% of women without a diagnosis (p < 0.001), fol-
lowed by prolonged bleedings, which 37.3% of women
with uterine fibroids indicated compared to 15.6% of
undiagnosed women (p < 0.001). Furthermore, diag-
nosed women with uterine fibroids reported more often
bleedings between periods and frequent periods which
occur more often than just every 24 days (33.3% and
28.4% vs. 13.5% and 15.2%), (p < 0.001), as well as irre-
gular and unpredictable periods (36.3% vs. 23.9%), (p <
Table 1 Study participation per country
No. of women per country
France Germany Italy UK USA Canada Brazil South Korea
invited 25,973 16,743 19,564 41,840 78,567 32,589 26,905 9,000
started screening 4,617 4,392 4,276 5,179 5,253 4,272 5,510 3,271
meeting screening criteria and quota 2,954 2,939 2,815 2,902 4,495 3,194 3,210 2,654
completed survey 2,543 2,558 2,519 2,500 4,039 2,514 2,552 2,524
Zimmermann et al. BMC Women?’?s Health 2012, 12:6
http://www.biomedcentral.com/1472-6874/12/6
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diagnosis of uterine fibroids regarding absent periods (p
= 0.015) and infrequent periods (p = 0.048), which was
defined as periods that occur less often than every 38
days. Multivariate analysis controlled for age did not
show any difference in results, except that no statistical
difference was found for shortened duration of men-
strual bleeding (p = 0.099).
Two further questions supported the findings on
bleeding symptoms: Of those women who indicated
menstrual bleeding problems, women with diagnosed
uterine fibroids reported a significantly longer duration
of period (5.6 ± 3.1 days, n = 1,245) than women with-
out a diagnosis of uterine fibroids (5.2 ± 2.4 days, n =
18,842), (p < 0.001). Additionally, women with uterine
fibroids perceived their blood loss as heavier than
women without uterine fibroids (mean 3.5 ± 1.0 vs. 3.2
± 0.8) (p < 0.001), based on a 5-point-scale where 1 was
defined as “very light” and 5 accordingly as “very heavy”
blood loss during menstrual bleeding.
Pain symptoms
Table 4 shows the frequency of different pain symptoms
for women diagnosed with uterine fibroids compared to
women without a diagnosis. Diagnosed women with
uterine fibroids experienced significantly more often
pressure on the bladder or inside the abdomen as well
as chronic pelvic pain (32.6% and 14.5% vs. 15.0% and
2.9%) (p < 0.001). Pain at different points of time during
the menstrual cycle was reported more commonly in
women with uterine fibroids: They indicated to suffer
significantly more often from pain occurring mid-cycle,
after and during menstrual bleeding (31.3%, 16.7%,
59.7% vs. 17.1%, 6.4%, 52.0%) (p < 0.001). About 23.5%
of women with uterine fibroids reported painful sexual
intercourse compared to 9.1% of women without the
4.5% 4.6%
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Figure 1 Self-reported prevalence of uterine fibroids across countries.
Table 2 Self-reported prevalence of uterine fibroids by age groups
Women by age group
15 to 19 years* 20 to 29 years 30 to 39 years 40 to 49 years
Total N 2,180 6,335 6,378 6,853
Self-Reported Prevalence in % (N) 0.4 (8) 1.8 (115) 7.0 (447) 14.1 (963)
*Age range in the USA: 18 to 49 years
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between both groups regarding menstrual cramps in the
abdominal area just before menstrual period starts. In
addition we conducted a logistic regression analysis con-
trolled for age and the co-morbidities endometriosis and
adenomyosis. Results showed high statistical significance
(p < 0.001) for all pain symptoms listed in Table 4.
Those women who reported pain symptoms were
asked about the severity of their symptoms in the last
12 month on a 10-point scale, where 1 was defined as
Table 3 Frequency of bleeding symptoms: Comparison of diagnosed women with uterine fibroids and women without
a diagnosis of uterine fibroids
Women with a diagnosis of
uterine fibroids
Women without a diagnosis of
uterine fibroids
p-
value*
Total N 1,533 20,213
% of women with symptom
Heavy menstrual bleeding 59.8% 37.4% p <
0.001
Prolonged duration of menstrual bleeding 37.3% 15.6% p <
0.001
Bleeding between periods 33.3% 13.5% p <
0.001
Frequent periods (i.e. periods occur more often than just
every 24 days)
28.4% 15.2% p <
0.001
Irregular/unpredictable periods 36.3% 23.9% p <
0.001
Light menstrual bleeding 10.9% 18.7% p <
0.001
Absent periods 13.9% 11.8% 0.015
Infrequent periods (i.e. periods occur less often than every 38
days)
16.7% 14.8% 0.048
Shortened duration of menstrual bleeding 13.1% 15.5% 0.012
*c
2-test applied
Table 4 Frequency of pain symptoms: Comparison of diagnosed women with uterine fibroids and women without a
diagnosis of uterine fibroids
Women with a diagnosis of
uterine fibroids
Women without a diagnosis of
uterine fibroids
p-
value*
Total N 1,533 20,213
% of women with symptom
Pressure on the bladder or inside the abdomen 32.6% 15.0% p <
0.001
Chronic pelvic pain (i.e. all or most days of the month) 14.5% 2.9% p <
0.001
Painful sexual intercourse 23.5% 9.1% p <
0.001
Pain occurring mid-cycle/during ovulation (approx. 10 days
after the end of my period)
31.3% 17.1% p <
0.001
Pain after my menstrual bleeding or period 16.7% 6.4% p <
0.001
Pain during menstrual bleeding or period 59.7% 52.0% p <
0.001
Pain when going to the toilet 10.8% 5.4% p <
0.001
Cramping during menstrual period 50.2% 47.0% 0.014
Menstrual/period cramps in the abdominal (belly) area just
before menstrual bleeding starts
48.7% 47.2% 0.246
*c
2-test applied
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(see Table 5). Results show that women with diagnosed
uterine fibroids score the severity of their pain symp-
toms significantly higher than women without a diagno-
sis, except for chronic pelvic pain where no difference
between both groups was found. Severity scores among
women with uterine fibroids were highest for cramping
and pain during menstrual bleeding.
Management of uterine fibroids
The majority of women with uterine fibroids received
their diagnosis in their thirties or forties. The mean age
at diagnosis across all countries is similar, ranging from
33.5 ± 8.4 years in Germany to 36.1 ± 6.9 years in
Korea (see Figure 2).
The percentage of women who received any medical
treatments from their physician after the diagnosis of
uterine fibroids varied from a low of 18.5% (95%CI:
12.7-25.4%) in Germany to a high of 55.8% (95%CI:
50.7-60.8%) in Brazil. The percentage of the remaining
countries ranged between 39.4% (95%CI: 31.2-48.1%)
(Italy) and 52.1% (95%CI: 47.7-56.4%) (USA). The
types of medical treatment most frequently recorded
were Oral Contraceptives (OCs), Painkillers and Iron
Supplements. Oral Contraceptive usage was highest in
Brazil (35.1%; 95%CI: 30.4-40.1%) and Italy (32.8%;
95%CI: 25.1-41.4%), whereas in Korea only 5.7% (95%
CI: 2.3-11.5%) of women were treated with OCs. Pain-
killers for the treatment of uterine fibroid symptoms
were most often used in the USA (34.7%; 95%CI: 30.7-
38.9%), and least often in Italy (15.3%; 95%CI: 9.7-
22.5%). Women in Canada reported the highest intake
of Iron supplements (21.3%; 95%CI: 10.7-35.7%) com-
pared to Brazil with the lowest percentage (9.8%; 95%
Table 5 Severity of pain symptoms in the last 12 month: Comparison of diagnosed women with uterine fibroids and
women without a diagnosis of uterine fibroids
Women with a diagnosis of
uterine fibroids
Women without a diagnosis
of uterine fibroids
p-
value*
Cramping during menstrual period N 527 8033 p <
0.001
Mean
±S D
6.9 ± 2.4 6.2 ± 2.3
Pain during menstrual bleeding or period N 609 8315 p <
0.001
Mean
±S D
6.7 ± 2.5 6.2 ± 2.3
Chronic pelvic pain (i.e. all or most days of the month) N 107 441 0.356
Mean
±S D
6.7 ± 2.7 6.6 ± 2.4
Menstrual/period cramps in the abdominal (belly) area just
before menstrual bleeding starts
N 477 7429 p <
0.001
Mean
±S D
6.3 ± 2.5 5.7 ± 2.4
Pain when going to the toilet N 106 807 0.002
Mean
±S D
6.5 ± 2.4 5.7 ± 2.5
Pain after my menstrual bleeding/period N 138 796 p <
0.001
Mean
±S D
6.3 ± 2.5 5.6 ± 2.4
Painful sexual intercourse N 211 1414 0.020
Mean
±S D
6.2 ± 2.6 5.8 ± 2.4
Pressure on the bladder or inside the abdomen N 309 2308 p <
0.001
Mean
±S D
5.9 ± 2.4 5.0 ± 2.4
Pain occurring mid-cycle/during ovulation (approx. 10 days
after the end of my period)
N 309 2581 p <
0.001
Mean
±S D
5.8 ± 2.6 5.0 ± 2.5
*c
2-test applied
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Page 6 of 11CI: 7.0-13.2%). Besides, the following country specifics
regarding medical treatment types commonly used
were found: In UK as well as in France 10.3% (95%CI:
4.2-20.1%) of women with uterine fibroids were treated
with an intrauterine system (Mirena
®). Progestin treat-
ment was quite common in Brazil (12.6%; 95%CI: 9.5-
16.4%) and France (10.3%; 95%CI: 4.2-20.1%). About
17.3% (95%CI: 11.7-24.2%) of women in Germany and
17.0% (95%CI: 7.6-30.8%) of women in Canada indi-
cated to use home remedies e.g. hot water bottle to
treat uterine fibroids symptoms.
In all countries, except for Brazil (47.7%; 95%CI: 42.6-
52.8%), more than half of the women stated that they
underwent surgical treatment for their uterine fibroids,
ranging from 54.0% (95%CI: 45.3-62.6%) in Italy to
68.5% (95%CI: 64.3-72.4%) in the USA. Hysterectomy
was the leading type of surgery in almost all countries;
except for Italy and France where myomectomy is the
most commonly reported surgical intervention (35.9% in
France; 95%CI: 21.2-52.8%; 21.6% in Italy; 95%CI: 12.9-
32.7%). As Figure 3 shows the percentage of hysterecto-
mized women based on all women with uterine fibroids
is highest in the USA with 29.1% (95%CI: 25.3-33.1%),
followed by Germany with 21.8% (95%CI: 15.6-29.1) and
the UK with 19.1% (95%CI: 10.6-30.5%) and lowest in
Italy with 5.1% (95%CI: 2.1-10.2%). Furthermore the
percentage of women who were hysterectomized was 5-
fold (Canada) to 17-fold (France) higher in the popula-
tion of diagnosed women with uterine fibroids com-
pared to women without a diagnosis.
Impact on Life
Asking the women with diagnosed uterine fibroids (n =
1,533) about the impact of their symptoms in the last
12 month on their daily life, 14.8% (95%CI: 13.1-
16.7%) of women reported a severe negative impact,
18.3% (95%CI: 16.4-20.4%) a moderate negative impact
and 20.6% (95%CI: 18.6-22.7%) a mild negative impact.
Almost 37.2% (95%CI: 34.8-39.7%) of diagnosed
women answered that the symptoms do not have any
impact on their daily life, whereas 9.0% (95%CI: 7.6-
10.5%) did not know. There was no difference in the
impact of symptoms on their daily life between the dif-
ferent age groups. Those women who reported a mild
to severe impact of symptoms, where additionally
asked which activities where negatively affected by
their symptoms. About 42.9% (95%CI: 39.5-46.4%) of
women stated that their sexual life was negatively
affected, followed by performance at work (27.7%; 95%
CI: 24.7-30.9%), relationship & family (27.2%; 95%CI:
24.2-30.4%) and housekeeping (25.9%; 95%CI: 22.9-
29.0%) (see Figure 4).
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Scope of the survey
The UBP-WRS is among the largest online research
endeavors to address women’s healthcare issues. The
survey directly recorded the experiences relating to uter-
ine bleeding and pain of more than 21,000 women from
diverse regional and demographic groups worldwide.
This wealth of data has allowed the identification of var-
ious trends, specifically relating to the prevalence, symp-
toms and management of uterine fibroids.
Limitations of the survey and methods
Nevertheless, a survey of this kind is subject to certain
methodological limitations, which need to be carefully
considered. First of all, the data may have been influ-
enced by patient self-selection (self-selection bias)
because of the fact that a) the responding women had
access to and use the internet; b) in most cases they had
experience in online market research participation in
exchange for a small fiscal reward and c) they were will-
ing to answer questions concerning their sexual health.
Therefore, the study population can differ in their char-
acteristics in comparison to the general female popula-
tion. Representativeness of survey population regarding
socio-demographic factors is only a minor risk due to
the large sample size and applied quotas in age, level of
education, country region and household income. All
study results rely solely on women’ss e l f - r e p o r t sa n d
therefore on their subjective response. This is especially
of concern regarding the data on diagnoses, symptoms
and treatments because the results were not validated
by medical records or clinical examinations. Subjective
retrospective criteria, such as previous diagnosis and
symptoms, can be biased as respondents may have diffi-
culties to recall certain memories (recall bias). Finally,
no linguistic validation of the translated questionnaire
was conducted.
Prevalence
The self-reported prevalence in this study ranged from
4.5% in UK to 9.8% in Italy. These results suggest that
uterine fibroids are quite common among women in
reproductive age, considering that the study population
only includes diagnosed women with myomas, while the
number of undiagnosed women remains uncertain. The
results of the study are not directly comparable to other
epidemiological studies due to the fact that the diagnosis
has not been clinically proven by ultrasonography or
other tests. Despite, it fits in the range of 5% to 21% of
other epidemiological prevalence data (see Table 6). The
results demonstrated that the self-reported prevalence of
uterine fibroids increased by age, reaching 14.1% in the
age group of 40+ years. Findings are consistent with
other studies [12,14,15]. Besides, the data showed that
some women in the twenties already received a diagno-
sis of uterine fibroids, though prevalence numbers are
rather low (1.8%). The mean age at diagnosis is very
similar across all countries and ranges between 33.5 and
36.1 years, which is somehow surprising, considering
that the countries differ greatly in getting access to the
health care system and in their health care provision.
Risk Factors
Results of this study indicate that age is a risk factor for
uterine fibroids as diagnosed women with myomas were
significantly older than undiagnosed women. This find-
ing is confirmed by other studies [12,17,32]. In contrast,
age at menarche did not appear as a risk factor for
women with uterine fibroids, which was found in some
other research studies [15,22,33]. Furthermore, after
adjusting for age, we could not find any difference in
the percentage of women who have given birth between
women with and without a diagnosis of uterine fibroids,
although parity is supposed to decrease the risk of uter-
ine myomas [15,19,22].
Symptoms
According to our knowledge, this is the first study that
systematically investigated self-reported bleeding and
pain symptoms of women with a diagnosis of uterine
fibroids. Nevertheless, when interpreting the study
results it needs to be considered that diagnosed women
within the study population rather reflect those cases
who got more clinical attention because of their symp-
toms, whereas asymptomatic myomas often remain
undiagnosed. The results showed that women with a
diagnosis of uterine fibroids reported more frequently
about heavy and prolonged bleedings compared to
women without uterine fibroids. Besides, diagnosed
women indicated more often to have unpredictable and
irregular bleedings, also described as frequent periods
that appear more often than just every 24 days or bleed-
ings between periods. These findings are consistent with
previous studies [11,26,34]. While the association
between uterine bleeding symptoms and myomas is long
known, the pathomechanism is not understood yet. Pos-
sible causes are venous ectasia resulting from mechani-
cal compression of veins by myomas, or altered
function, expression or storage of vasoactive growth fac-
tors produced by myomas [1,35].
T h ef i n d i n g si nt h i ss t u d ys u g g e s tt h a ta p a r tf r o m
uterine bleeding symptoms, women with uterine fibroids
suffer more frequently from multiple gynecological pain
symptoms than women without a diagnosis of uterine
fibroids. Pain symptoms reported more frequently in
women with uterine fibroids were: pressure on the
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Page 9 of 11bladder, chronic pelvic pain and pain at different time
points during the menstrual cycle. In addition, women
with myomas more often suffer from painful sexual
intercourse. Even after adjusting for age and co-morbid-
ities women with uterine fibroids reported more often
multiple pain symptoms compared to women without a
diagnosis. The literature examining the relation of uter-
ine myomas and gynecologic pain symptoms in a popu-
lation-based study is very limited. An Italian study
found that in a non-care-seeking population women
w i t hu t e r i n ef i b r o i d sw e r em o r el i k e l yt or e p o r tm o d e r -
ate or severe dyspareunia and moderate or severe non-
cyclic pelvic pain than women without uterine fibroids,
but not moderate to severe dysmenorrhea [27]. The
research studies on pain during sexual intercourse are
inconsistent: A study from Ferrero et al. (2006) demon-
strated that women with uterine fibroids do not have an
increased prevalence or severity of deep dyspareunia,
whereas Ertunc et al. (2009) found that a potential
impairment, mainly because of pain during sexual inter-
course, exists in women with myomas [36,37]. The
results of this study suggest that uterine fibroids can
cause multiple bleeding and pain symptoms, which may
have a negative impact on the sexual life of women,
their relationship and family as well as work. Neverthe-
less further research on the symptoms and their impact
on life is needed.
Management of uterine fibroids
The treatment patterns across the 8 countries vary a lot,
d u et od i f f e r e n c e si nt h eh e a l t hc a r es y s t e m sa sw e l la s
due to cultural differences in patients and physicians
treatment preferences. The data showed that the percen-
tage of women who receive medical treatment after
diagnosis varies broadly, being highest in Brazil (55.8%;
95%CI: 50.7-60.8%) and lowest in Germany (18.5%; 95%
CI: 12.7-25.4%). Oral Contraceptives and Painkillers are
across all countries the leading medical treatment option
to manage bleeding and pain symptoms, although they
do not treat the myomas [29]. Furthermore women in
France and the UK commonly reported to use an
intrauterine system (Mirena
®) and women in Brazil and
France indicated a high usage of progestins for the treat-
ment of uterine fibroids. These hormonal therapies are
in general commonly prescribed for gynecological indi-
cations in those countries. Except for Brazil, more than
half of the women have undergone surgery to treat myo-
mas, considering that the study population might reflect
rather symptomatic women with uterine fibroids. Still in
most countries, hysterectomy is the leading surgical
intervention, except for Italy and France. The results are
consistent with the European study from Downes et al.
(2010) [31]. As expected Hysterectomy rates are highest
in the USA, where uterus myoma is the leading diagno-
sis for this surgery [8]. The lowest number of hysterec-
tomized women was found in Italy, independently if
women have received a diagnosis of uterine fibroids or
not.
Conclusions
The study results are consistent with available data and
underline that uterine fibroids are a common concern
for women in fertile age, especially in the age group of
the over 40s. Uterine fibroids can cause multiple bleed-
ing and pain symptoms which might have a negative
impact on women’s life, influencing their sexual, social
and work life. Despite these consequences uterine
fibroid data, especially on epidemiology, symptomatol-
ogy and their impact on women’s health are still limited
and further research is required.
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